NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Read more about NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
Development of New Indications for Small Molecule Drugs at Risk under Inflation Reduction Act’s Drug Price Negotiation Program, Study Finds Read more about Development of New Indications for Small Molecule Drugs at Risk under Inflation Reduction Act’s Drug Price Negotiation Program, Study Finds
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications Read more about Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis Read more about Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2025 Read more about NPC Comments on HHS Notice of Benefit and Payment Parameters for 2025
NPC Submits Comments to CMS on Proposed Changes to Medicare Programs Read more about NPC Submits Comments to CMS on Proposed Changes to Medicare Programs
Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community Read more about Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community
How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation Read more about How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation
Addressing Critical Ambiguities in CMS’s Drug Evaluation Process Read more about Addressing Critical Ambiguities in CMS’s Drug Evaluation Process